Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)
China · Delayed Price · Currency is CNY 32.04
+0.32 (1.01%)
Apr 29, 2026, 3:00 PM CST
SHA:600976 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 3,337 | 3,356 | 3,484 | 4,190 | 3,623 | 3,292 |
Other Revenue | 14 | 14 | 21.13 | 23.59 | 17.41 | 7.8 |
| 3,351 | 3,370 | 3,505 | 4,213 | 3,641 | 3,299 | |
Revenue Growth (YoY) | -2.22% | -3.85% | -16.81% | 15.72% | 10.35% | 34.34% |
Cost of Revenue | 1,335 | 1,409 | 1,835 | 2,279 | 2,067 | 1,882 |
Gross Profit | 2,016 | 1,960 | 1,670 | 1,934 | 1,574 | 1,417 |
Selling, General & Admin | 1,660 | 1,602 | 1,418 | 1,515 | 1,203 | 1,129 |
Research & Development | 98.95 | 98.68 | 79.49 | 74.05 | 73.19 | 52.61 |
Other Operating Expenses | 22.19 | 17.92 | 15.79 | 29.03 | 24.52 | 22.96 |
Operating Expenses | 1,799 | 1,736 | 1,558 | 1,621 | 1,311 | 1,210 |
Operating Income | 216.61 | 224.59 | 111.6 | 313.12 | 262.77 | 207.46 |
Interest Expense | -12.58 | -13.19 | -12.93 | -3.7 | -4.81 | -8.71 |
Interest & Investment Income | 95.45 | 120.47 | 228.44 | 235.04 | 167.26 | 127.46 |
Other Non Operating Income (Expenses) | 4.65 | 4.89 | -3.94 | -7.51 | -21.95 | -4.77 |
EBT Excluding Unusual Items | 304.13 | 336.75 | 323.16 | 536.94 | 403.27 | 321.44 |
Gain (Loss) on Sale of Investments | 15.15 | 17.34 | 28.4 | 6.18 | -12.11 | -2.46 |
Gain (Loss) on Sale of Assets | -0.19 | -0.18 | -2.67 | 0.16 | -1.14 | -0.93 |
Asset Writedown | -0.65 | -0.65 | -0.42 | -11.39 | -9.61 | -0.09 |
Other Unusual Items | 45.39 | 37.81 | 44.14 | 39.21 | 57.53 | 23.5 |
Pretax Income | 363.82 | 391.06 | 392.62 | 571.09 | 437.94 | 341.45 |
Income Tax Expense | 21.33 | 25.84 | 24.87 | 47.86 | 31.93 | 35.51 |
Earnings From Continuing Operations | 342.49 | 365.22 | 367.75 | 523.23 | 406.01 | 305.94 |
Minority Interest in Earnings | -5.09 | -5.38 | -5.57 | -1.78 | 2.07 | -0.68 |
Net Income | 337.4 | 359.84 | 362.18 | 521.46 | 408.08 | 305.26 |
Net Income to Common | 337.4 | 359.84 | 362.18 | 521.46 | 408.08 | 305.26 |
Net Income Growth | -9.50% | -0.65% | -30.55% | 27.78% | 33.68% | 106.55% |
Shares Outstanding (Basic) | 153 | 152 | 152 | 153 | 152 | 152 |
Shares Outstanding (Diluted) | 153 | 152 | 152 | 153 | 152 | 152 |
Shares Change (YoY) | 1.17% | -0.23% | -0.49% | 0.43% | 0.26% | -1.35% |
EPS (Basic) | 2.20 | 2.37 | 2.38 | 3.41 | 2.68 | 2.01 |
EPS (Diluted) | 2.20 | 2.37 | 2.38 | 3.41 | 2.68 | 2.01 |
EPS Growth | -10.55% | -0.42% | -30.20% | 27.24% | 33.33% | 109.38% |
Free Cash Flow | 237.37 | 173.86 | 113.98 | 203.89 | 147.9 | 191.77 |
Free Cash Flow Per Share | 1.55 | 1.15 | 0.75 | 1.33 | 0.97 | 1.26 |
Dividend Per Share | 0.900 | 0.900 | 0.900 | 1.200 | 1.000 | 0.806 |
Dividend Growth | - | - | -25.00% | 20.00% | 24.07% | 120.22% |
Gross Margin | 60.16% | 58.17% | 47.63% | 45.91% | 43.23% | 42.96% |
Operating Margin | 6.46% | 6.66% | 3.18% | 7.43% | 7.22% | 6.29% |
Profit Margin | 10.07% | 10.68% | 10.33% | 12.38% | 11.21% | 9.25% |
Free Cash Flow Margin | 7.08% | 5.16% | 3.25% | 4.84% | 4.06% | 5.81% |
EBITDA | 254.83 | 262.13 | 146.42 | 346.1 | 294.96 | 235.92 |
EBITDA Margin | 7.61% | 7.78% | 4.18% | 8.21% | 8.10% | 7.15% |
D&A For EBITDA | 38.22 | 37.54 | 34.83 | 32.98 | 32.19 | 28.47 |
EBIT | 216.61 | 224.59 | 111.6 | 313.12 | 262.77 | 207.46 |
EBIT Margin | 6.46% | 6.66% | 3.18% | 7.43% | 7.22% | 6.29% |
Effective Tax Rate | 5.86% | 6.61% | 6.33% | 8.38% | 7.29% | 10.40% |
Revenue as Reported | 3,351 | 3,370 | 3,505 | 4,213 | 3,641 | 3,299 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.